Results 51 to 60 of about 22,035 (254)

FMO-guided design of darunavir analogs as HIV-1 protease inhibitors

Scientific Reports
The prevalence of HIV-1 infection continues to pose a significant global public health issue, highlighting the need for antiretroviral drugs that target viral proteins to reduce viral replication.
Hathaichanok Chuntakaruk, K. Hengphasatporn, Yasuteru Shigeta, Chanat Aonbangkhen, V. Lee, Tanatorn Khotavivattana, T. Rungrotmongkol, S. Hannongbua   +7 more
semanticscholar   +1 more source

Systemic inflammation and residual viraemia in HIV-positive adults on protease inhibitor monotherapy: a cross-sectional study. [PDF]

, 2015
Increased levels of markers of systemic inflammation have been associated with serious non-AIDS events even in patients on fully suppressive antiretroviral therapy.
Arenas-Pinto, A, Gilson, R, Maini, M, McKendry, A, Milinkovic, A, Peppa, D   +5 more
core   +1 more source

Development and validation of UV-spectrophotometry method for quantitative determination of amorphous darunavir

Разработка и регистрация лекарственных средств
Introduction. Darunavir as an effective antiretroviral drug is widely used in clinical practice, including for the treatment of pediatric patients, as well as pregnant women, and for personalized therapy.
M. A. Mandrik, I. A. Sadkovskii, E. D. Pinegina, L. A. Korol, I. I. Krasnuk   +4 more
doaj   +1 more source

Comparison of atazanavir/ritonavir and darunavir/ritonavir based antiretroviral therapy for antiretroviral naïve patients

BMC Infectious Diseases, 2017
Background Atazanavir/ritonavir and darunavir/ritonavir are common protease inhibitor-based regimens for treating patients with HIV. Studies comparing these drugs in clinical practice are lacking.
Tony Antoniou, Leah Szadkowski, Sharon Walmsley, Curtis Cooper, Ann N. Burchell, Ahmed M. Bayoumi, Julio S. G. Montaner, Mona Loutfy, Marina B. Klein, Nima Machouf, Christos Tsoukas, Alexander Wong, Robert S. Hogg, Janet Raboud, The Canadian Observational Cohort (CANOC) collaboration   +14 more
doaj   +1 more source

Identification of drug resistance mutations in HIV from constraints on natural evolution [PDF]

, 2015
Human immunodeficiency virus (HIV) evolves with extraordinary rapidity. However, its evolution is constrained by interactions between mutations in its fitness landscape.
Barton, John P., Butler, Thomas C., Chakraborty, Arup K., Kardar, Mehran   +3 more
core   +2 more sources

Predicted antiviral drugs Darunavir, Amprenavir, Rimantadine and Saquinavir can potentially bind to neutralize SARS-CoV-2 conserved proteins

Journal of Biological Research, 2021
Background Novel Coronavirus disease 2019 or COVID-19 has become a threat to human society due to fast spreading and increasing mortality. It uses vertebrate hosts and presently deploys humans. Life cycle and pathogenicity of SARS-CoV-2 have already been
U. C. Halder
semanticscholar   +1 more source

High rate of virologic suppression with darunavir/ritonavir plus optimized background therapy among highly antiretroviral-experienced HIV-infected patients: results of a prospective cohort study in São Paulo, Brazil

Brazilian Journal of Infectious Diseases, 2013
Objectives: To assess the virologic and immunological response of darunavir/ritonavir plus optimized background therapy in highly antiretroviral-experienced HIV-infected patients in Brazil.
José Ernesto Vidal, Alice Tung Wan Song, Maria Laura Matos, Daniel Bartmann, Guilherme dos Anjos, Érique José Peixoto de Miranda, Ângela Carvalho Freitas, Mirian de Freitas Dalben, Claudinei Santana, Aluísio Cotrim Segurado, Cláudia Cortese Barreto, Adrián Vladimir Hernández   +11 more
doaj   +1 more source

Virologic response to tipranavir-ritonavir or darunavir-ritonavir based regimens in antiretroviral therapy experienced HIV-1 patients: a meta-analysis and meta-regression of randomized controlled clinical trials. [PDF]

PLoS ONE, 2013
The development of tipranavir and darunavir, second generation non-peptidic HIV protease inhibitors, with marked improved resistance profiles, has opened a new perspective on the treatment of antiretroviral therapy (ART) experienced HIV patients with ...
Asres Berhan, Yifru Berhan
doaj   +1 more source

Nanoflow-nanospray mass spectrometry metabolomics reveals disruption of the urinary metabolite profiles of HIV-positive patients on combination antiretroviral therapy [PDF]

, 2017
Background: The use of combination antiretroviral therapy (cART) has substantially improved the outlook for patients with HIV infection. However, lifelong exposure to cART is also associated with adverse metabolic changes and an enhanced risk of renal ...
Abdul-Sada, Alaa, Bremner, Stephen A, Chetwynd, Andrew J, Gilleece, Yvonne, Hill, Elizabeth M, Holt, Stephen G, Samarawickrama, Amanda, Vera, Jaime H   +7 more
core   +1 more source

Anion‐Controlled Structural Interconversion of Palladium Cages Enables Separations by Selective Guest Capture and Release

Angewandte Chemie International Edition, EarlyView.
We report a pair of interconvertible palladium(II) cages assembled from an asymmetric ligand, whose switching is triggered by specific counter‐anions, tetrafluoroborate (BF4−) and bis(trifluoromethanesulfonyl)imide (NTf2−). Their complementary guest preferences enable orthogonal, multi‐cycle catch‐and‐release, exemplified by the selective purification ...
Zhe Li, Tanya K. Ronson, Charlie T. McTernan   +2 more
wiley   +1 more source